Patheon plans to make additional investments in its Milton Park facility in Oxfordshire, UK, to expand early development capabilities. The site currently provides proof-of-concept and first-in-man development programs for oral dose forms, as well as Quick to Clinic, which aims to provide clinical trial materials as fast as four months from receipt of API.   With the first investment phase, the company will introduce the SoluPath program, a fixed-price, multi-platform solution designed to improve...